Category: Latest News
-
Spyre Therapeutics shares jump after positive ulcerative colitis trial data
Spyre Therapeutics (NASDAQ:SYRE) shares climbed 25% on Monday after the company reported that its investigational therapy SPY001 achieved its primary endpoint in a Phase 2 study targeting ulcerative colitis. The biotech group released 12-week results from Part A of its SKYLINE trial, showing that SPY001 delivered a statistically significant 9.2-point reduction in the Robarts Histopathology…
-
3D Systems unveils new dual-laser printer and factory software at RAPID + TCT
3D Systems Corporation (NYSE:DDD) introduced its latest SLA 825 Dual stereolithography system alongside the AddiTrak software platform at the RAPID + TCT 2026 event in Boston. The SLA 825 Dual offers a 22% increase in build volume and delivers up to 25% faster production speeds compared to earlier models. It is aimed at high-throughput manufacturing…
-
AbbVie ends CollPlant deal and slashes workforce to cut costs
CollPlant Biotechnologies (NASDAQ:CLGN) said its collaboration with AbbVie (NYSE:ABBV) has been terminated, prompting the company to implement cost-cutting measures including a reduction of around 50% of its workforce. The termination was initiated by Allergan Industrie SAS, an AbbVie subsidiary, which exercised its contractual right to exit the agreement with 60 days’ notice. The partnership, established…
-
Fastenal shares drop despite meeting estimates as growth outlook softens
Fastenal Company (NASDAQ:FAST) reported first-quarter results in line with analyst expectations on Monday, but its shares slid around 6% in pre-market trading as investors reacted to signs of slowing growth and margin pressures. The industrial supplies distributor posted adjusted earnings per share of $0.30 on revenue of $2.2 billion, both matching consensus forecasts. Sales rose…
-
IDEAYA shares soar on positive late-stage melanoma trial data
IDEAYA Biosciences (NASDAQ:IDYA) stock surged 27% on Monday after the company reported encouraging topline results from its Phase 2/3 registrational study evaluating darovasertib in combination with crizotinib for first-line treatment of metastatic uveal melanoma. The OptimUM-02 study achieved its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS). Patients receiving the combination…
-
Sandisk shares jump after Nasdaq-100 addition
Sandisk Corporation (NASDAQ:SNDK) shares climbed around 4% on Monday after the company was confirmed for inclusion in the Nasdaq-100 Index. Nasdaq said Sandisk will join the benchmark index ahead of the market open on April 20, 2026, replacing Atlassian Corporation (NASDAQ:TEAM). Being added to the Nasdaq-100 often boosts demand for a stock, as funds and…
-
Regeneron, Telix strike radiopharmaceutical cancer deal worth up to $2.1bn
Regeneron Pharmaceuticals (NASDAQ:REGN) has entered into a strategic collaboration with Telix Pharmaceuticals (NASDAQ:TLX) to develop and commercialize radiopharmaceutical therapies targeting cancer. As part of the agreement, Telix will receive an initial $40 million payment covering four early-stage therapeutic programs. Both companies will jointly fund development and split any resulting profits equally, while Telix will retain…
-
Wall Street set for lower open as renewed U.S.-Iran tensions unsettle markets: Dow Jones, S&P, Nasdaq, Futures
U.S. stock futures pointed to a weaker start on Monday, with equities likely to retreat after posting strong gains in the previous week. Investor sentiment has been dampened by rising fears of renewed escalation in the Middle East, following the collapse of weekend negotiations between Washington and Tehran. “They have chosen not to accept our…
-
Five key themes for markets in the week ahead
Geopolitics is taking centre stage at the start of the trading week, with a planned U.S. blockade of the Strait of Hormuz driving fresh volatility across markets. The move has pushed oil prices higher again, while upcoming inflation data and a busy earnings calendar could provide further direction for investors. 1. U.S. moves ahead with…
-
McDonald’s plans energy drinks and new sodas for U.S. menu overhaul – WSJ
McDonald’s (NYSE:MCD) is preparing to expand its beverage lineup in the U.S. with the launch of energy drinks and new flavoured sodas, as part of a broader effort to refresh its cold drink offering, according to a report by The Wall Street Journal. The company is expected to introduce several new drinks in the coming…